ARTICLE | Clinical News

AZ's long-term Brilinta thinking

January 15, 2015 2:43 AM UTC

AstraZeneca plc (LSE:AZN; NYSE:AZN) said anticoagulant Brilinta ticagrelor met the primary endpoint in a cardiovascular (CV) outcomes study evaluating long-term use of the drug beyond one year.

AZ said twice-daily dosing of 60 mg or 90 mg of oral Brilinta plus aspirin led to significantly fewer major thrombotic CV events compared to placebo plus aspirin on the composite endpoint of cardiovascular (CV) death, myocardial infarction (MI) and stroke. The 21,000-patient PEGASUS-TIMI 54 study evaluated long-term use of the reversible purinergic receptor P2Y G protein-coupled 12 ( P2RY12) ( P2Y12) to reduce thrombotic CV events in patients aged 50 and older who have a history of heart attack and at least one additional risk factor. ...